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Abstract
IgA nephropathy (IgAN) is characterized by a variable clinical course and multifaceted pathophysiology. There is substantial
evidence to suggest that complement activation plays a pivotal role in the pathogenesis of the disease. Therefore, complement
inhibition using the humanized anti-C5 monoclonal antibody eculizumab could be a rational treatment. We report here a
16-year-oldmalewith the vasculitic formof IgANwho failed to respond to aggressive conventional therapy including high-dose
steroids, cyclophosphamide and plasma exchange andwhowas treatedwith four weekly doses of 900 mg eculizumab followed
by a single dose of 1200 mg. He responded rapidly to this treatment and has had a stable creatinine around 150 µmol/L
(1.67 mg/dL) for >6 months. However, proteinuria was unabated on maximal conventional anti-proteinuric treatment, and a
repeat renal biopsy 11 months after presentation revealed severe chronic changes. We believe this case provides proof of
principle that complement inhibitionmay be beneficial in IgAN but also that development of chronicitymay be independent of
complement.
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Introduction
The pathogenesis of IgA nephropathy (IgAN) involves multiple
‘hits’ [1, 2]. It is thought that increased levels of circulating galact-
ose-deficient IgA1 in association with the production of unique
anti-glycan antibodies leads to the formation of pathogenic
IgA1 containing circulating immune complexes that are depos-
ited within the mesangium leading to activation of mesangial
cells and thus glomerular damage. That complement compo-
nents including C3, C4d, C5b-9, properdin, factor H, C4BP and
MBL are deposited within the glomerulus in IgAN has been
known for some time [3–5]. In addition it has been shown that
there are genetic susceptibility factors for IgAN that involve com-
plement. A common deletion in the regulators of complement
activation cluster at 1q32, which incorporates the genes (CFHR3
and CFHR1) encoding factor H-related protein 3 and 1, has been
shown to protect against IgAN [6], possibly by reducing the ability
of complement factor H-related proteins to inhibit the regulatory
function of CFH [7]. It thus seems possible that complement inhib-
itionmight be beneficial in the treatment of IgANand in particular
the crescentic form with rapidly progressive glomerulonephritis
(RPGN), which has a poor prognosis [8]. We report here the use
of eculizumab in a young man with Henoch–Schönlein purpura
and crescentic IgAN.
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Case history
A 16-year-old man was admitted in September 2013 with a
2-week history of mild abdominal pain, arthralgia and purpura
on the lower extremities. He had previously been treated with
penicillin for an unconfirmed diagnosis of erysipelas. Blood
pressure was 116/69 mmHg, serum creatinine was 59 µmol/L
(1.08 g/dL) and creatinine clearance 159 mL/min. Urinalysis
showed haematuria and proteinuria. Serum albumin was 30 g/L
but there was no evidence of oedema. Since 2010 he had been
treated with atomoxetine for attention deficit–hyperactive dis-
order. Otherwise there was no significant past medical history.
He reported occasional use of marihuana, amphetamines and
cocaine. He smoked 15–30 cigarettes daily. Serological tests to ex-
clude ANCA-associated vasculitis and SLE were negative. C3 and
C4 levels were normal. A diagnosis of Henoch–Schönlein purpura
was made and he was started on an angiotensin-converting
enzyme inhibitor. Two months later he was readmitted with in-
creasing creatinine of 98 µmol/L (1.11 g/dL) and declining serum
albumin of 19 g/L.
A biopsy (Figure 1A) revealed epithelial crescents in 6 of 14
glomeruli, mesangial hyperplasia, endocapillary hypercellularity
and deposition of both IgA (++++/4+) and C3 (+++/4+) on immuno-
fluorescence (M1 S0 E1 T0 according to Oxford classification).
Because of the rapid loss of renal function and the acute
changes on biopsy with no evidence of chronic damage it was
elected to treat him with prednisolone 40 mg daily and cyclo-
phosphamide 100 mg (1.5 mg/kg) [9]. He was also anticoagulated
with warfarin and low molecular weight heparin. Despite this,
renal function deteriorated further. He was, therefore, given
three daily pulses of methylprednisolone 500 mg followed by
five plasma exchanges (40 mL/kg). This did not result in any im-
provement. As a last resort—andwithout any direct proof of com-
plement involvement—we decided to treat with eculizumab.
Four weekly doses of 900 mg were administered intravenously
followed by a single dose of 1200 mg accompanied throughout
by penicillin. Immediately after the first dose of eculizumab a re-
markable improvement in renal function was evident. After
3 months cyclophosphamide was replaced with azathioprine
and the dose of prednisolone was tapered. The course is shown
in Figure 2.
A further renal biopsy (Figure 1B) taken 11 months after pres-
entation revealed chronicity with 2 of 19 glomeruli completely
and 7 partially sclerosed, tubular and interstitial changes with
50% atrophy and fibrosis. There was evidence of residual activity
with a single glomerulus showing a cellular crescent. According
to Oxford classification the changes were considered as M1 S1
E1 T1. Accordingly, renal function slowly declined to end-stage
in spring 2015 with unabated nephrotic range proteinuria but
consistently well-controlled blood pressure.
Further complement analysis has been undertaken. C3 was
1.77 g/L, C4 0.30 g/L, factor H 0.79 g/L and factor I 81 mg/L. CD46
expression on peripheral blood mononuclear cells was normal
and factor H autoantibody screening was negative. Mutation
screening of CFH, CFI, CD46, C3 and CFB showed no abnormal-
ities. Multiplex ligation-dependent analysis (MLPA) showed
no evidence of genomic disorders affecting CFH or CFHR1-5.
Discussion
KDIGO guidelines recommend that steroids and cyclophospha-
mide be used to treat crescentic (>50% crescents) IgAN [10–12]
with RPGN. We report here a case of crescentic IgAN unrespon-
sive to this regimen. Furthermore, the introduction of plasma
exchange did not appear to be beneficial. Therefore, because of
the possible involvement of complement in the pathogenesis of
IgAN we elected to treat the patient with eculizumab as a last re-
sort.With this therewas a significant immediate improvement in
renal function. Proteinuria, however, persisted and a repeat renal
biopsy has shown evidence of chronicity. As with all anecdotal
Fig. 1. (A) Glomerulus with a cellular crescent in a first renal biopsy; ×20, PAS. (B)
Segmental glomerulosclerosis and atrophy of tubuli and fibrosis of interstitium in a
second renal biopsy 11 months later, ×20, PAS (left) and IgA immunofluorescence
(right). Fig. 2. Course of the disease.
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reports it is difficult to know whether the improvement in renal
function can be ascribed to the intervention. It is indeed possible
that the effect of the massive therapy provided incidentally
materialized at exactly the moment eculizumab was started.
There is, however, evidence emerging from other forms of
glomerulonephritis that complement blockade may play a role
in inducing remission in aggressive forms including crescentic
dense deposit disease [13–15] and lupus nephritis [16]. This is
perhaps not surprising given that complement activation results
in the generation of powerful inflammatory anaphylatoxins such
as C5a. This is supported by the temporal relationship seen in the
time course. Macrohaematuria may cause acute kidney injury
and persistent injury [11] but one would then expect tubular
injury rather than crescentic disease on biopsy. Notwithstanding
free haemoglobin could exacerbate the disease process by acti-
vating complement [17].
Use of eculizumab in another patient with IgAN has been
reported [18]. In that case eculizumab was started when deterior-
ation in renal function occurred despite treatmentwithmycophe-
nolate mofetil and steroids. The introduction of eculizumab was
associated with temporary stabilization in renal function but the
therapy was eventually withdrawn when a further renal biopsy
showed severe chronicity. These two cases suggest that the
mechanisms underlying chronic progression may not be amen-
able to complement inhibition as we provided it. Recently it
was shown that inhibiting C5aR resulted in more rapid amelior-
ation of proteinuria than steroid in patients with ANCA-positive
vasculitis [19].
Conclusion
Following the comprehensive treatment in our patient, crescents
improved, but nonetheless severe and progressive chronicity de-
veloped. If this deterioration is the result of the initial severe cres-
centic disease, perhaps earlier treatment with eculizumab could
improve the final outcome. However, it is also possible that even
if complement is involved in the causation of nephritis, either
components proximal to the effect of eculizumab could be para-
mount or there is no direct relationship between initial inflam-
mation and development of chronic scarring. Many more
complement studies would be needed to assess these possibil-
ities. Wewere not able to accomplish that during the acute treat-
ment of our desperately ill patient.
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